Heidi Hagen - 02 Sep 2021 Form 4 Insider Report for ZIOPHARM ONCOLOGY INC (TCRT)

Reporting relationship: Director
Issuer ticker: TCRT
Reported as of: 02 Sep 2021
Net transaction value: +$41,835
SEC form: 4
Accepted by SEC: 03 Sep 2021, 17:25:10 UTC
Prior SEC filing: 20 May 2021
Next SEC filing: 29 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Courtney Thorne, Attorney-in-Fact

Key filing fact

Heidi Hagen filed Form 4 for ZIOPHARM ONCOLOGY INC (TCRT) on 03 Sep 2021.

Key facts

This page summarizes Heidi Hagen's Form 4 filing for ZIOPHARM ONCOLOGY INC (TCRT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2021, 17:25.

Change

Previous filing in this sequence was filed on 20 May 2021.
Current net transaction value: +$41,835.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TCRT transaction

Common Stock

Purchase

Transaction value: $41,835
Shares: +23,770
Change %: +19%
Price: $1.76
Shares after: 145,889
Date: 02 Sep 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.